Another trial, DESTINYLung01, is assessing the use of trastuzumab deruxtecan (DS-8201a) in patients with unresectable and/or metastatic NSCLC with HER2 mutations or overexpression [71]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.